Fast, stable induction of P-glycoprotein-mediated drug resistance in BT-474 breast cancer cells by stable transfection of ABCB1 gene

Anticancer Research

Volumn 35, Issue 5, 2015, Pages 2531-2538

  Tang, Yuan ^a   Wang, Yue ^b   Deosarkar, Sudhir ^a   Soroush, Fariborz ^a   Kiani, Mohammad F ^a   Wang, Bin ^a,c  

^a Temple University   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c WIDENER UNIVERSITY   (United States)

Author keywords

Breast cancer; BT 474; HER2; MDR; P glycoprotein; Transfection

Indexed keywords

ABC TRANSPORTER; CARBOPLATIN; DOCETAXEL; FLUOROURACIL; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY TEST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIGENE FAMILY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE TRANSFECTION; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEINS; RECEPTOR, ERBB-2; TRANSFECTION;

EID: 84929670601     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Dean-Colomb W and Esteva FJ: Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 44: 2806-2812, 2008.
2. van Slooten HJ, Bonsing BA, Hiller AJ, Colbern GT, van Dierendonck JH, Cornelisse CJ and Smith HS: Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer. Br J Cancer 72: 22-30, 1995.
3. Wang B, Rosano JM, Cheheltani R, Achary MP and Kiani MF: Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv 7: 1159-1173, 2010.
4. Mitri Z, Constantine T and O'Regan R: The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract 2012: 743193, 2012.
5. Rybarova S, Hodorova I, Hajdukova M, Schmidtova K, Mojzis J, Kajo K, Kviatkovska Z, Plank L, Benicky M, Mirossay A, Biros E, Bobrov N, Wagnerova M, Berc A and Mirossay L: Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma 53: 128-135, 2006.
6. Perez EA: Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114: 195-201, 2009.
7. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN and National Cancer Institute of Canada Clinical Trials G: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. The New England journal of medicine 354: 2103-2111, 2006.
8. Wang Y, Peng H, Zhong Y, Li D, Tang M, Ding X and Zhang J: Differential gene expression profiling of human epidermal growth factor receptor 2-overexpressing mammary tumor. Acta Biochim Biophys Sin (Shanghai) 40: 397-405, 2008.
9. Chen JS, Lan K and Hung MC: Strategies to target HER2/neu overexpression for cancer therapy. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 6: 129-136, 2003.
10. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212, 2003.
11. Wang S, Huang X, Lee CK and Liu B: Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29: 4225-4236, 2010.
12. Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y and He Z: Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 43: 647-653, 2011.
13. Trock BJ, Leonessa F and Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931, 1997.
14. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J and Schinkel AH: Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60: 5761-5766, 2000.
15. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews Cancer 2: 48-58, 2002.
16. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L and Seidman AD: Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20: 2319-2326, 2002.
17. Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M and Clynes M: Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer 112: 286-294, 2004.
18. Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M, Uzan S, Lotz JP, Touboul E and Lacave R: Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94: 473-480, 2006.
19. Tang Y, Lei T, Manchanda R, Nagesetti A, Fernandez-Fernandez A, Srinivasan S and McGoron AJ: Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study. Pharm Res 27: 2242-2253, 2010.
20. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F and Yu D: Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 1326-1334, 2009.
21. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV and Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486-4490, 1988.
22. Marquette C and Nabell L: Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol 13: 263-275, 2012.
23. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr., Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS and Fu LW: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68: 7905-7914, 2008.
24. Lukyanova NY: Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells. Exp Oncol 32: 10-14, 2010.
25. Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F and Molnar J: Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26: 4559-4568, 2006.
26. Society AC: Different types of chemotherapy drugs. 2014.
27. Beccari E, Modigliani P and Morpurgo G: Induction of inter- and intragenic mitotic recombination by fluorodeoxyuridine and fluorouracil in Aspergillus nidulans. Genetics 56: 7-12, 1967.
28. Hill BT, Whelan RD, Shellard SA, McClean S and Hosking LK: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169-182, 1994.
29. Calabro-Jones PM, Byfield JE, Ward JF and Sharp TR: Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 42: 4413-4420, 1982.
30. Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT and Lancaster JM: In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer 106: 1967-1975, 2012.
31. Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN and Atyabi F: Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 6: 1903-1912, 2011.
32. Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P and Menard S: Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer 105: 568-573, 2003.
33. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM and Gilmer TM: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69: 6871-6878, 2009.
34. Higa GM and Abraham J: Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy 7: 1183-1192, 2007.
35. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C and Ueno NT: Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7: 1846-1850, 2008.